Verbatim response from ChatGPT
Short answer
- No reliable evidence that “compounded” GLP‑1 drops or homemade tablets work as well as the approved medicines. They’re unregulated, variable in dose/quality, and most likely won’t provide predictable absorption.
- If you want an oral GLP‑1 that’s proven to work, the only FDA‑approved option is Rybelsus (oral semaglutide). For the strongest, well‑studied weight‑loss and diabetes effects, the injectable GLP‑1/GIP drugs (examples: Wegovy/Ozempic — semaglutide; Mounjaro/Zepbound — tirzepatide) are the standard.
Why compounded oral GLP‑1 products are risky and usually ineffective
- Peptide drugs (like semaglutide, tirzepatide) are large and are normally destroyed in the gut unless formulated with specific absorption technology. Rybelsus succeeds because it includes an absorption enhancer (SNAC) and has clinical pharmacology data to show it gets into the bloodstream. A compounding pharmacy making a “drop” or simple tablet almost certainly does not replicate that validated formulation.
- Compounded products aren’t held to the same FDA standards for potency, purity, stability or sterility as approved drugs. That means dose can vary, they may be contaminated, and shelf life is uncertain.
- There are no credible clinical trials showing safety and efficacy of these compounded oral drops/tablets for diabetes or weight loss. Marketing claims from some clinics are not the same as evidence.
Why injections work better (in most published studies)
- Injectable, FDA‑approved GLP‑1 or GIP/GLP‑1 drugs have controlled dosing, proven absorption, large clinical trials showing glucose control and (for several agents) substantial weight loss, and known safety profiles. Examples:
- Semaglutide injectable: Ozempic (diabetes), Wegovy (weight loss) — Novo Nordisk
- Tirzepatide injectable: Mounjaro, Zepbound — Eli Lilly
- Dulaglutide: Trulicity — Eli Lilly
- Self‑injectable pens are designed for home use and many patients find them easy to use.
If you’re considering an oral option
- Consider Rybelsus (oral semaglutide, Novo Nordisk). It’s the only approved oral GLP‑1 and has published data for diabetes control; weight loss effects are smaller than high‑dose injectable semaglutide (Wegovy) because oral dosing is limited by absorption.
- Discuss with your clinician whether Rybelsus is appropriate for your condition, insurance coverage, and costs.
If someone is offering compounded GLP‑1 drops/tablets
- Be very cautious. Ask for a certificate of analysis (COA) from an independent lab and documentation of sterility/potency — but even with COAs, the delivery and absorption mechanisms are unproven.
- Avoid buying these products from unverified internet sellers or clinics that pressure you to pay up front or skip medical evaluation.
What to do next
- Talk with your primary care doctor or an endocrinologist about FDA‑approved options (Rybelsus if you need oral; Ozempic/Wegovy, Mounjaro/Zepbound, Trulicity, etc. for injectables).
- If cost or needle aversion is the issue, ask about manufacturer copay programs, patient assistance, or training to make injections easier.
- If you already are taking a compounded product, stop it and discuss safer, approved alternatives with your clinician.
If you want, I can:
- Compare Rybelsus vs Ozempic/Wegovy vs Mounjaro (expected effects, typical dosing, common side effects).
- Help draft questions to bring to your doctor or a compounding pharmacy.